Multiple Sclerosis Drug companies

Key Multiple Sclerosis Drug Market Players:

The international market is extremely unified, with the presence of notable key players, such as Biogen, Novartis, and Roche, collectively dominating with 65% of the market share through oral DMTs and monoclonal antibodies. These companies have readily implemented tactical initiatives, including transition to neuroprotection and approved administrative products. For instance, Biogen witnessed a sudden shift towards neuroprotection with USD 1.1 billion in research and development-based investment. Besides, Novartis’s Kesimpta gained 23% of the share with self-administered convenience, while Roche’s Ocrevus achieved 27% of the share through pediatric acceptances and expanded dosage, thus suitable for the market development.

Here is a list of key players operating in the global market:

• Roche
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• Novartis
• Biogen
• Merck KGaA
• Sanofi
• Teva Pharmaceutical
• Bristol-Myers Squibb
• Pfizer
• Mylan (Viatris)
• Dr. Reddy’s Laboratories
• Hetero Drugs
• Biocon
• Celltrion
• CSL Limited
• Hikma Pharmaceuticals